Supporting Information S1: Further Details of Chemistry Experimental Section (S)-1-(2-(4-Chlorophenoxy)acetyl)-N-methylindoline-2-carboxamide (26)Prepared
34.5, 25.9. LCMS (ES+): m/z (%) 363 [M+H] + t R : 4.20 (20-95% MeCN, acidic); HRMS (ES+) Calc. for [C 18 
1-(2-(3,4-Dichlorophenoxy)acetyl)-N-methylindoline-2-carboxamide (30)
Prepared using general procedure A, colourless solid, 21 mg, 22%; δ H (500 MHz, CDCl 3 ) 8.22 (bs, 1H, NH), 7.38 (d, J = 8.6 Hz, 1H, ArH), (masked, 3H, ArH), 7.17 (t, J = 7.4 Hz, 1H, ArH), 7.07 (d, J = 3.0 Hz, 1H, ArH), 6.86 (d, J = 8.6 Hz, 1H, ArH), 5.80 and 4.76 (2 x bs, rotomer, 1H, CH 2 ), 5.33 and 5.01 (2 x bs, rotomer, 1H, CH 2 ), 3.72 (bs, 1H, CH 2 ), 3.31 (bs, 1H, CH 2 ), 2.78 (bd, rotomer, 3H, CH 3 ). δ C (125 MHz, d6-DMSO) 171.3 (C=O), 168.8 (C=O), 143. 2, 140.0, 130.7, 130.0, 127.0, 124.9, 124.5, 123.5, 116.3 (ArC), 61.0, 40.8, 34.1, 25.8; LCMS (ES+) : m/z (%) 379 [M+H] + t R : 4.46 (20-95% MeCN, acidic); HRMS (ES+) Calc. for [C 18 H 17 N-methyl-1-(2-phenoxyacetyl)indoline-2-carboxamide (31) Prepared using general procedure A, colourless solid, 49 mg, 16%; δ H (500 MHz, CDCl 3 ) 8.20 (bs, 1H, NH), 7.35-7.32 (m, 4H, ArH), 7.15 (t, J = 7.5 Hz, 1H, ArH), 7.04 (t, J = 7.5 Hz, 1H, ArH), 6.98 (dd, J = 7.8 and 1.0 Hz, 1H, ArH), 5.80, 5.31, 5.06, 4 .78 (4 x bs, rotomer, 3H, CH 2 and CH), 3.68 (bs, 1H, CH 2 ), 3.32 (bs, 1H, CH 2 ), 2.72 (bs, rotomer, 3H, CH 3 ). δ C (125 MHz, d6-DMSO) 171.1 (C=O), 166.3 (C=O), 158.0, 143.0, 129.6, 129.3, 127.1, 124.5, 123.7, 120.9, 116.2, 114.4 (ArC), 65.7, 59.6, 34.5, 25.8. LCMS (ES+) : m/z (%) 311 [M+H] + t R : 3.81 (20-95% MeCN, acidic); HRMS (ES+) Calc. for [C 18 
N-Methyl-1-(2-((tetrahydrofuran-3-yl)oxy)acetyl)indoline-2-carboxamide (32)
1 : 1 mixture of diastereoisomers, colourless solid, 34 mg, 46%; δ H (500 MHz, d6-DMSO) 8.05 (d, J = 7.1 Hz, 1H, ArH), 8.18 (bs, 1H, NH), 7.20 (m, 2H, ArH), 7.01 (t, J = 7.3 Hz, 1H, ArH), 4.97 (m, 1H, CH), 4.22 (m, 2H, CH 2 ), 3.88 (m, 1H, CH), (m, 4H, 2 x CH 2 ), 3.54 (m, 1H, CH 2 ), 3.02 (d, J = 16.6 Hz, 1H, CH 2 ), 2.60 (bs, 3H, CH 3 ), 1.92 (m, 2H, CH 2 ); δ C (125 MHz, d6-DMSO) 171. 2, 167.9, 143.1, 129.7, 127.1, 124.5, 123.6, 116.4, 79.5, 72.0 (dia1), 71.9 (dia2), 67.6, 66.2, 59.8, 34.4, 31.9 (dia1) , 31.8 (dia2), 25.8; LCMS (ES+): m/z (%) 305 [M+H] + t R : 0.92 (20-95% MeCN, acidic); HRMS (ES+) Calc. for [C 16 
(R)-N-methyl-1-(2-((6-methylpyridin-3-yl)oxy)acetyl)indoline-2-carboxamide (33)
Prepared using general procedure A, colourless solid, 4 mg, 2%; δ H (500 MHz, CDCl 3 ) 8.22 (d, J = 3.0 Hz, 1H, py-H), 2H, masked, ArH), 1H, masked, ArH), 7.18 (dd, J = 8.5 and 3.0 Hz, 1H, ArH), 2H, ArH), 5.82, 5.24, 5.12, 4 .82 (4 x bs, rotomer, 3H, CH 2 and CH), 3.62 (bs, 1H, CH 2 1, 165.8 (C=O), 154.7, 142.8, 129.6, 127.1, 124.5, 123.8, 117.49, 117.4, 116.2, 110.8, 104.1, 104.0 (ArC), 66.3, 59.6, 34.4, 25.9 166.3 (C=O), 157.9, 143.0, 129.6, 129.0, 128.7, 127.1, 124.5, 123.7, 116.2, 114.0 (ArC), 65.7, 59.6, 34.5, 25.9 1, 143.4, 133.3, 132.3, 131.8, 129.9, 128.3, 128.1, 127.3, 127.0, 126.0, 125.4, 124.5, 123.3, 116.2, 60.9, 54.9, 34.3, 25.9 . LCMS (ES+): m/z (%) 345 [M+H] + t R : 4.23 (20-95% MeCN, acidic); HRMS (ES+) Calc. for [C 22 146.5, 143.3, 132.3, 129.9, 129.5, 127.0, 126.1, 124.4, 123.3, 116.3, 60.9, 45.7, 40.9, 34.1, 33.1, 25.8, 23.9 ; LCMS (ES+): m/z (%) 337 [M+H] + t R : 4.46 (20-95% MeCN, acidic); HRMS (ES+) Calc. for [C 21 131.6, 131.5, 127.4, 127.0, 124.4, 123.4, 116.3, 114.9, 114.7, 109.7 (ArC), 60.93, 40.5, 34.1, 25.8 2, 133.2, 129.9, 127.0, 124.5, 123.4, 118.8, 118.7, 116.2, 111.11, 110.9, 103.4 (ArC), 60.9, 34.2, 31.8, 25.8 2, 168.7, 157.7, 155.8, 143.1, 130.0, 127.2, 127.0, 124.5, 123.5, 118.3, 118.1, 116.4, 61.0, 34.1, 25.8 131.6, 131.85, 131.2, 130.0, 127.0, 124.4, 123.4, 116.3, 114.9, 114.7 (ArC), 60.9, 34.1, 25.8 170.0, 166.0, 156.9, 143.3, 129.1, 129.0, 127.3, 124.6, 124.5, 123.7, 116.2, 115.9, 66.0, 57.6, 36.3, 35.6, 33.3 170.6, 165.9, 156.9, 143.0, 129.6, 129.1, 127.1, 124.6, 124.5, 123.7, 116.2, 116.1, 65.9, 59.5, 34.6, 33.8, 14.5 170.5, 165.9, 156.9, 143.0, 129.6, 129.1, 127.2, 124.6, 124.5, 123.7, 116.2, 116.1, 66.0, 59.5, 34.7, 31.0, 19.5, 13.6 8, 166.0, 156.9, 143.1, 129.5, 129.1, 127.2, 124.6, 124.5, 123.7, 116.2, 116.0, 66.0, 59.3, 34.5, 22.5, 5.7, 5.6 Methyl bromoacetate (3.2 mL, 34.8 mmol) was added drop-wise to a solution of sodium azide (2.1 g, 32.4 mmol) in DMF (8 mL) at 0 °C, under argon, the reaction was slowly warmed up to RT over a 16 h period, quenched with brine and extracted with Et 2 O (2x). The organics were dried over Na 2 SO 4 , filtered, concentrated in-vacuo to give methyl azidoacetate A1 as a colourless oil which was used without further purification (can be stored in the freezer during several weeks). A solution of methyl azidoacetate A1 (8.01 mmol, 3 eq) and aldehyde (2.6 mmol, 1 eq) in THF (2 mL) was added drop-wise to a solution of sodium methoxide (0.5 g, 3.5 eq) in MeOH (7 mL) at -10°C under argon. The reaction mixture was stirred at -10 °C for 3 h and was poured into a water-ice bath, the precipitate was filtered, washed with water (3x) and freeze-dried overnight to give the desired vinylazide A2 as a colourless solid. A solution A2 (0.71 mmol) in toluene (0.8 mL) in presence of Rh 2 (O 2 CC 3 F 7 ) 4 (37 mg, 5 % mol) was heated at 65 °C for 48 h. The reaction mixture was cooled to RT and was diluted with CH 2 Cl 2 before quenching with sat. aq. NaHCO 3 . The mixture was then filtered through a hydrophobic frit and concentrated to dryness to give the methyl 2-carboxyindole A3. Mg turnings (300 mg, 10 eq) were added to a solution of A3 (1.23 mmol) in MeOH (15 mL) in one portion at 0°C under argon. The reaction mixture was allowed to warm up slowly to RT over a 16 h period. The reaction mixture was diluted with CH 2 Cl 2 and cooled down to 0 °C before adding aq. 2 N HCl until pH<5. The resulting mixture was then poured into a sat. aq. Na 2 CO 3 solution at 0 °C (until pH>9). The precipitate was filtered off and washed with a mixture of CH 2 Cl 2 and water. The filtrate was extracted with CH 2 Cl 2 (3x) and the organics were dried over Na 2 SO 4 , filtered through a hydrophobic frit and concentrated in-vacuo to give indoline A4. The crude A4 and MeNH 2 (10 eq, 2 M in THF) were stirred at RT under argon for 16 h. After concentration to dryness, the crude was reacted with the acid chloride (1.1 eq) and iPr 2 NEt (2 eq) in CH 2 Cl 2 (0.1 M) at RT under Ar for 2 h. The reaction mixture was then diluted with CH 2 Cl 2 , neutralized with sat. aq. NaHCO 3 and filtered through a hydrophobic frit. Excess solvent was removed in-vacuo and column chromatography eluenting with 0-100 % EtOAc in hexanes or 0-20 % MeOH (20 %)/CH 2 Cl 2 in CH 2 Cl 2 ) afforded the title compound A5. 
1-(2-(4-Fluorophenoxy)acetyl)-N-d3methylindoline-2-carboxamide (53)

1-(2-(4-Chlorophenoxy)acetyl)-5-fluoro-N-methylindoline-2-carboxamide (54)
5-Fluoro-1-(2-(4-fluorophenoxy)acetyl)-N-methylindoline-2-carboxamide (55)
General Procedure: Preparation of 5-fluoro substituted indolines (Scheme 2b) [1] [2] [3] 1 M BH 3 in THF (7.1 mL, 7.1 mmol, 1.25 eq.) was added drop-wise to a solution of acid (1.5 g, 5.64 mmol) in THF (11.3 mL) at 0 °C under argon. The reaction mixture was allowed to warm up slowly to RT overnight then quenched by slow addition of water at 0 °C. The organic and aqueous phases were partitioned and the aqueous phase was extracted with EtOAc (2 x). The organics were washed with brine and dried over Na 2 SO 4 , filtered through a hydrophobic frit and concentrated under reduced pressure to give the crude alcohol (1.24 g). Mesyl chloride (460 µL, 5.94 mmol, 1.2 eq.) was added drop-wise to a solution of the crude alcohol and iPr 2 NEt (1.7 mL, 9.76 mmol, 2 eq.) in THF (25 mL) at 0 °C, under argon. The reaction mixture was stirred at 0 °C for 2 h and was quenched with brine, extracted with EtOAc, washed with brine and dried over Na 2 SO 4 . After filtration through a hydrophobic frit, the organics were evaporated to dryness to give the title compound I1. To a solution of the crude mesylate I1 (519 mg, 1.57 mmol), N-(diphenylmethylene)glycine ethyl ester (440 mg, 1.65 mmol, 1.05 eq.), TBAI (29 mg, 5% mol) in toluene (4 mL) was added a solution of aq. 50% KOH (1.7 mL) at 0 °C under argon. The biphasic solution was vigorously stirred and allowed to warm up slowly to RT overnight. The reaction mixture was diluted in EtOAc and the organics and aqueous phases were partitioned. The aqueous phase was extracted with EtOAc (3 x) and the organics were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give the title compound I2. I2 was dissolved in THF (8 mL) and a 1 M aq. citric acid solution (8 mL) was added at 0 °C under argon, the reaction mixture was stirred at RT for 3 h then cooled to 0 °C and neutralized by addition of solid Na 2 CO 3 until pH >8. The resulting mixture was extracted with CH 2 Cl 2 , washed with sat. aq. Na 2 CO 3 solution and dried over Na 2 SO 4 . After filtration through a hydrophobic frit, the solvents were evaporated and the mixture re-dissolved in CH 2 Cl 2 (12 mL) and added to a solution of 4-fluorophenoxyacetic acid (235 mg, 1.38 mmol, 1.15 eq), iPr 2 NEt (501 µL, 2.87 mmol, 2.4 eq) and TBTU (462 mg, 1.44 mmol, 1.2 eq) in CH 2 Cl 2 (12 mL) stirred at RT under argon for 30 min. This resulting mixture was stirred at RT overnight and was then quenched with sat. aq. NaHCO 3 solution, extracted with CH 2 Cl 2 (2 x) and washed with brine. The organics were dried over Na 2 SO 4 , filtered through a hydrophobic frit and concentrated in-vacuo. Purification by flash column chromatography eluting with EtOAc in hexanes 0-100% afforded the desired amide I3 (350 mg, 46% from the commercially available acid). 5-fluoro-2-iodophenyl)2-(2-(4-fluorophenoxy) CsOAc (412 mg, 2.15 mmol, 3 eq.) and CuI (150 mg, 0.79 mmol, 1.1 eq.) were successively added to a solution of amide I3 (350 mg, 0.72 mmol) in DMSO (3.6 mL) at RT under argon. The reaction mixture was stirred at RT for 1.5 h and was quenched with brine, extracted with CH 2 Cl 2 (3 x), washed with brine and dried over Na 2 SO 4 . Excess solvent was removed in vacuo to afford the indoline, that was used in the next step without further purification. 1 N aq. LiOH (0.8 mL, 0.8 mmol, 1.1 eq.) was added to a solution of the crude indoline in THF (5 mL) at RT, under argon, the reaction mixture stirred at RT for 1h, cooled to 0 °C, quenched 1 N aq. HCl and extracted with EtOAc (3 x). The organics were dried over Na 2 SO 4 , filtered, excess solvent removed in-vacuo to give the crude acid I4. iPr 2 NEt (300 µL, 1.72 mmol, 2.4 eq.) and TBTU (275 mg, 0.86 mmol, 1.2 eq.) were added to a solution I4 dissolved in CH 2 Cl 2 (10 mL) at RT, under argon and the reaction mixture stirred at RT for 30 min and MeNH 2 in MeOH (2M, 0.9 mL, 1.8 mmol, 2.4 eq.) added. This resulting mixture was stirred for a 1h, quenched with sat. aq. NaHCO 3 solution, extracted with CH 2 Cl 2 (2 x) and washed with brine. The organics were dried over Na 2 SO 4 , filtered and excess solvent removed in-vacuo. Flash column chromatography eluenting with MeOH (20%)/CH 2 Cl 2 in CH 2 Cl 2 gradient 0-100% afforded the title compound 55 (135 mg, 55% from amide I3).d H (500 MHz, J = 4.4 Hz, 1H, NH), 7.99 (dd, J = 8.7 and 4.9 Hz, 1H, ArH), 7.12 (m, 3H, ArH), 7.01 (m, 1H, ArH), 6.94 (m, 2H, ArH), 5.11 (d, J = 10.7 Hz, 1H, CH), 4.95 (d, J = 15.6 Hz, 1H, CH 2 ), 4.43 (d, J = 15.6 Hz, 1H, CH 2 ), 3.59 (dd, J = 16.8 and 10.7 Hz, 1H, CH 2 ), 3.11 (d, J = 16.8 Hz, 1H, CH 2 ), 2.63 (d, J = 4.4 Hz, 3H, CH 3 ); d F (470 MHz, d C (125 MHz, 166.0, 158.7 (d, J = 239.6 Hz), 156.7 (d, J = 236.5 Hz), 154.3, 139.3, 132.2 (d, J = 9.2 Hz), 117.0 (d, J = 8.4 Hz), 115.7 (d, J = 22.9 Hz), 115.7 (d, J = 8.6 Hz), 113.3 (d, J = 22.5 Hz), 111.9 (d, J = 24.5 Hz), 66.2, 60.0, 34.4, 25.9 (125 MHz, 166.5, 156.7 (d, J = 235.9 Hz), 154.2, 139.1, 126.2, 115.7 (d, J = 22.8), 115.7 (d, J = 8.4 Hz), 113.5 (d, J = 19.1 Hz), 105.3 (d, J = 23.3 Hz), 66.1, 60.3, 34.1, 25.9 1, 166.7, 156.8, 129.1, 124.8, 116.3, 113.4 3-methoxyphenyl allyl carbonate (1.547 g, 2-2.5 eq) was added to a suspension of crude compound rac-A6 (753 mg) and lipase CAL-A (CLEA, Aldrich) (380 mg) in TBME (30 mL) at RT, under argon, the mixture was stirred at RT at 250 rpm, the reaction was monitored by LCMS until the conversions were around 50 % (approximately 5 h), filtered and the filtrate concentrated in-vacuo. Column chromatography eluting with 0-50 % EtOAc in Hexane afforded (R)-A8 (269 mg). A8 and H 2 NMe (10 eq, 2 M in THF) were stirred at RT under argon for 16 h. After concentration to dryness, the crude was reacted with the acid chloride (1.1 eq) and iPr 2 NEt (2 eq) in CH 2 Cl 2 (0.1 M) at RT under argon for 2 h and worked up as described in general procedure B.
Ethyl 3-(
5-Bromoindoline-2-carboxylic acid N-Bromosuccinimide (1 mol eq.) was added portion wise to a solution of indoline-2-carboxylic acid (1 mol eq.) in DMF (anhydrous, 2 mLmmol -1 ) at 0 °C, the reaction was allowed to warm to rt and stirred for 2h, stopped, partitioned between EtOAc and H 2 O, the organic layer was dried over MgSO 4 , filtered and excess solvent removed in-vacuo to give the title compound (83 % yield). The material was used without further purification. [M+H] + t R : 5.6 (5-95% MeCN, basic);
General Procedure D: Suzuki Coupling 5-Bromoindoline-2-carboxylic acid (1 mol. eq.) was dissolved in a mixture of toluene:EtOH (7:3, 10 mL/mmol), degassed with argon, K 3 PO 4 (3 mol. eq.), boronic acid (1 mol. eq.) were added followed by bis-(tri-tert-butyl phosphine)Pd(0) (0.01 mol. eq.), the reaction mixture was heated at 120 °C for 15 min in a µW reactor, filtered through a celite pad, dissolved in EtOAc and washed with H 2 O. Column chromatography eluting with ether afforded the desired product. 
1-(2-(4-Fluorophenoxy)acetyl)-N-methyl-5-phenylindoline-2-carboxamide (61)
1-(2-(4-Fluorophenoxy)acetyl)-N-methyl-5-(pyridine-4-yl)indoline-2-carboxamide (62)
Prepared using general procedure D, colourless solid, 10 mg, 31%; δ H (500 MHz, CDCl 3 ) 8.68 (d, J = 6. 1 Hz, 2H, ArH), 2H, ArH), 7.49 (dd, J = 4.6 and 1.6 Hz, 2H, ArH), 1H, ArH), 2H, ArH), 2H, ArH) , 5.79 and 5.14 (2 x bs, rotomer, 1H, CH 2 ), 5.34 and 4.52 (2 x bs, rotomer, 2H, CH 2 ), 3.78-3.72 
